Functional EGFP-dystrophin fusion proteins for gene therapy vector development

Area of Science:

• Molecular Biology
• Gene Therapy
• Biochemistry

Background:

• Gene therapy for Duchenne muscular dystrophy is challenged by the large size of dystrophin cDNAs, leading to low expression yields.
• Current methods for detecting dystrophin-expressing cells are inefficient and costly.

Purpose of the Study:

• To develop an improved method for delivering dystrophin cDNA for Duchenne muscular dystrophy gene therapy.
• To create expression vectors fusing enhanced green fluorescent protein (EGFP) with dystrophin mini- and full-length cDNAs.
• To assess the efficacy and localization of these EGFP-dystrophin fusion proteins in vitro and in vivo.

Main Methods:

• Construction of expression vectors encoding EGFP-dystrophin fusion proteins (mini- and full-length).
• Transfection of Phoenix cells with Effectene reagent to test in vitro expression.
• Immunoblotting analysis using a dystrophin C-terminus specific antibody to confirm protein expression and size.
• In vivo electroporation of plasmids into mouse muscles, followed by cryosectioning and fluorescence microscopy.

Main Results:

• Transfection yielded a green fluorescent signal in 20% of cells, indicating successful expression of EGFP-dystrophin fusion proteins.
• Immunoblotting confirmed the expression of 240 kDa (EGFP-mini-dystrophin) and 450 kDa (EGFP-full-length dystrophin) fusion proteins.
• In vivo electroporation resulted in correct plasma membrane localization of EGFP-dystrophin in mouse muscle fibers.

Conclusions:

• Fusion of EGFP to dystrophin or mini-dystrophin does not impede normal protein localization.
• EGFP fusion serves as an effective tool for optimizing the delivery of dystrophin cDNA in vitro and in vivo.
• This approach facilitates the development of gene therapy strategies for Duchenne muscular dystrophy.